Pulmonary arterial hypertension associated with congenital heart disease

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 328-337

  D'Alto, Michele ^a   Mahadevan, Vaikom S ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Congenital heart disease; Down's syndrome; Eisenmenger's syndrome; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; IRON; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL;

ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTERY THROMBOSIS; ARTICLE; BEHAVIOR MODIFICATION; BLEEDING; CLINICAL CLASSIFICATION; COMORBIDITY; CONGENITAL HEART DISEASE; DOWN SYNDROME; EISENMENGER COMPLEX; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LEFT RIGHT SHUNT; HEART RIGHT LEFT SHUNT; HEMOPTYSIS; HUMAN; IRON DEFICIENCY; LUNG ARTERY THROMBOSIS; LUNG HEMODYNAMICS; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHLEBOTOMY; PREVALENCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC PULMONARY SHUNT; SYSTEMIC VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DOWN SYNDROME; EISENMENGER COMPLEX; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HEALTH BEHAVIOR; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; OXYGEN INHALATION THERAPY; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PULMONARY CIRCULATION; PURINES; SULFONAMIDES; SULFONES; THROMBOSIS;

EID: 84870744536     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004712     Document Type: Article

References (77)

1. Eisenmenger V. Die angeborenen Defecte der Kammerscheidewand des Herzens. Z Klin Med 1897; 32: 1-28.
2. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br Med J 1958; 2: 701-709.
3. Galie' N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
4. Galie' N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and Eisenmenger's syndrome. Drugs 2008; 68: 1049-1066.
5. Rodriguez FH 3rd, Moodie DS, Parekh DR, et al. Outcomes of hospitalization in adults in the United States with atrial septal defect, ventricular septal defect, and atrioventricular septal defect. Am J Cardiol 2011; 108: 290-293.
6. Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538-546.
7. Report of the British Cardiac Society Working Party. Grown-up congenital heart (GUCH) disease: current needs and provision of service for adolescents and adults with congenital heart disease in the UK. Heart 2002; 88: Suppl. 1, i1-i14.
8. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115: 1039-1050.
9. Van de Bruaene A, Delcroix M, Pasquet A, et al. The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol 2009; 64: 447-453.
10. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults: first of two parts. N Engl J Med 2000; 342: 256-263.
11. Kaemmerer H, Bauer U, de Haan F, et al. Recommendations for improving the quality of the interdisciplinary medical care of grown-ups with congenital heart disease (GUCH). Int J Cardiol 2011; 150: 59-64.
12. Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-172.
13. Adatia I, Kothari SS, Feinstein JA. Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective. Chest 2010; 137: Suppl. 6, 52S-61S.
14. Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.
15. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
16. Engelfriet PM, Duffels MG, Mö ller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93: 682-687.
17. Beghetti M, Galie' N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 733-740.
18. Collins-Nakai RL, Rabinovitch M. Pulmonary vascular obstructive disease. Cardiol Clin 1993; 11: 675-687.
19. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745-755.
20. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects and predictors of death in Eisenmenger's syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27: 1737-1742.
21. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124: 1755-1764.
22. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
23. Haworth SG. Pulmonary hypertension in the young. Heart 2002; 88: 658-664.
24. Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart 2008; 94: 1189-1193.
25. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16: 19-25.
26. Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89: 34-38.
27. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012; 155: 378-382.
28. Yap SC, Harris L, Chauhan VS, et al. Identifying high risk in adults with congenital heart disease and atrial arrhythmias. Am J Cardiol 2011; 108: 723-728.
29. DeFilippis AP, Law K, Curtin S, et al. Blood is thicker than water: the management of hyperviscosity in adults with cyanotic heart disease. Cardiol Rev 2007; 15: 31-34.
30. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828-835.
31. Somerville J. How to manage the Eisenmenger syndrome. Int J Cardiol 1998; 63: 1-8.
32. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855.
33. Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life-single centre experience and review of published data. Eur Heart J 2012; 33: 1386-1396.
34. Dimopoulos K, Giannakoulas G, Wort SJ, et al. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 2008; 23: 545-554.
35. Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and selfreported walking distances in chronic heart failure. Heart 2007; 93: 476-482.
36. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687.
37. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007; 50: 634-642.
38. Baumgartner H, Bonhoeffer P, De Groot N, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957.
39. Van De Bruaene A, Delcroix M, Pasquet A, et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011; 32: 2790-2799.
40. Tay EL, Peset A, Papaphylactou M, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011; 151: 307-312.
41. Mamas MA, Clarke B, Mahadevan VS. Embolisation of systemicto-pulmonary collaterals in patients with the Eisenmenger reaction presenting with haemoptysis. Cardiol Young 2008; 18: 528-531.
42. Galie' N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
43. Gatzoulis MA, Beghetti M, Galie' N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127: 27-32.
44. Berger RM, Beghetti M, Galie' N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J Cardiol 2010; 144: 373-378.
45. Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007; 93: 974-976.
46. Di{dotless}́az-Caraballo E, González-Garci{dotless}́a AE, Reñ ones M, et al. Longterm bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome. Rev Esp Cardiol 2009; 62: 1046-1049.
47. Monfredi O, Griffiths L, Clarke B, et al. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol 2011; 108: 1483-1488.
48. D'Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol 2011; [Epub ahead of print DOI: 10.1016/ j.ijcard.2011.07.009].
49. Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol 2011; [Epub ahead of print DOI: 10.1016/ j.ijcard.2011.06.064].
50. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail 2012; 18: 379-384.
51. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865.
52. Lu XL, Xiong CM, Shan GL, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther 2010; 28: 350-355.
53. Tay EL, Papaphylactou M, Diller GP, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol 2011; 149: 372-376.
54. Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011; 97: 1876-1881.
55. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120: 301-305.
56. Zeng WJ, Lu XL, Xiong CM, et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol 2011; 34: 513-518.
57. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006; 114: 1807-1810.
58. Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011; 107: 1381-1385.
59. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010; 31: 1124-1131.
60. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
61. Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol 2012; [Epub ahead of print DOI: 10.1016/j.jicard.2012.02.007].
62. Beghetti M, Galie' N, Bonnet D. Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis 2012; 7: 3-11.
63. Smadja DM, Gaussem P, Mauge L, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009; 119: 374-381.
64. Morris JK, Alberman E. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ 2009; 339: b3794.
65. Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr 2010; 169: 1445-1452.
66. Penrose LS. The incidence of Mongolism in the general population. J Ment Sci 1949; 95: 685-688.
67. Thase ME. Longevity and mortality in Down's syndrome. J Ment Defic Res 1982; 26: 177-192.
68. Glasson EJ, Sullivan SG, Hussain R, et al. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 2002; 62: 390-393.
69. Weijerman ME, van Furth AM, van der Mooren MD, et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 2010; 169: 1195-1199.
70. Vis JC, Thoonsen H, Duffels MG, et al. Six-minute walk test in patients with Down syndrome: validity and reproducibility. Arch Phys Med Rehabil 2009; 90: 1423-1427.
71. Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum, management and survival over 22 years. Arch Dis Child 2012; 97: 326-330.
72. Shapiro NL, Huang RY, Sangwan S, et al. Tracheal stenosis and congenital heart disease in patients with Down syndrome: diagnostic approach and surgical options. Int J Pediatr Otorhinolaryngol 2000; 54: 137-142.
73. Cua CL, Blankenship A, North AL, et al. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007; 28: 250-254.
74. Troost E, Van De Bruaene A, Lampropoulos K, et al. The outcome of Eisenmenger patients with trisomy 21 does not differ from patients without trisomy 21. Acta Cardiol 2011; 66: 293-301.
75. Cappelli-Bigazzi M, Santoro G, Battaglia C, et al. Endothelial cell function in patients with Down's syndrome. Am J Cardiol 2004; 94: 392-395.
76. Suzuki K, Yamaki S, Mimori S, et al. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 2000; 86: 434-437.
77. Duffels MG, Vis JC, Rosa LE, et al. Effect of bosentan on exercise capacity and quality of life of adults with pulmonary arterial hypertension associated with congenital heart disease with or without Downs syndrome. Am J Cardiol 2009; 103: 1309-1315.